Cargando…

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment

Detalles Bibliográficos
Autores principales:	Betrian, S, Ysebaert, L, Heider, K H, Delord, J P, Fournié, J J, Quillet-Mary, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5148053/ https://www.ncbi.nlm.nih.gov/pubmed/27834943 http://dx.doi.org/10.1038/bcj.2016.106

Ejemplares similares

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
por: Kroschinsky, Frank, et al.
Publicado: (2020)

Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
por: Kroschinsky, Frank, et al.
Publicado: (2020)

Idelalisib: The First-in-Class Phosphatidylinositol 3-Kinase Inhibitor for Relapsed CLL, SLL, and Indolent NHL
por: Forcello, Nicholas, et al.
Publicado: (2014)

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
por: Gentile, Massimo, et al.
Publicado: (2020)

A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia
por: Danilov, Alexey V., et al.
Publicado: (2021)

Nurse-like cells promote CLL survival through LFA-3/CD2 interactions
por: Boissard, Frédéric, et al.
Publicado: (2016)

A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Balzarotti, Monica, et al.
Publicado: (2021)

Idelalisib or Placebo in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL - Interim Results of a Phase 3 Randomized, Double-blind Placebo-Controlled Trial
por: Zelenetz, Andrew D., et al.
Publicado: (2017)

IL-10 Rescues CLL Survival through Repolarization of Inflammatory Nurse-like Cells
por: Domagala, Marcin, et al.
Publicado: (2021)

Treatment with idelalisib in patients with chronic lymphocytic leukemia – real world data from the registry of the German CLL Study Group
por: von Tresckow, Julia, et al.
Publicado: (2023)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

Nurse-like cells mediate ibrutinib resistance in chronic lymphocytic leukemia patients
por: Boissard, F, et al.
Publicado: (2015)

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse
por: Cadot, Sarah, et al.
Publicado: (2020)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
por: Sharman, J. P., et al.
Publicado: (2022)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

Cancer Stem Cells of Differentiated B-Cell Malignancies: Models and Consequences
por: Gross, Emilie, et al.
Publicado: (2011)

The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
por: Fiorcari, Stefania, et al.
Publicado: (2013)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

Lymphoma Heterogeneity Unraveled by Single-Cell Transcriptomics
por: Ysebaert, Loic, et al.
Publicado: (2021)

Nurse-like cells impact on disease progression in chronic lymphocytic leukemia
por: Boissard, F, et al.
Publicado: (2016)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
por: Timofeeva, Natalia, et al.
Publicado: (2021)

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
por: Eldfors, S, et al.
Publicado: (2017)

Toxic Encephalopathy After Relapsed Indolent Non-Hodgkin’s Lymphoma Following Abrupt Discontinuation of Idelalisib (ZYDELIG®)
por: Shenouda, Mina, et al.
Publicado: (2019)

Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study
por: Casadei, Beatrice, et al.
Publicado: (2022)

Microvesicles in CLL: predictor of disease progression/relapse
por: Maiti, Guru P., et al.
Publicado: (2017)

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Odetola, Oluwatobi, et al.
Publicado: (2023)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
por: Kreuzer, Karl-Anton, et al.
Publicado: (2019)

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
por: Lovell, Alexandra R., et al.
Publicado: (2022)

Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2020)

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
por: Kost, Sara E. F., et al.
Publicado: (2019)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed/refractory acute myeloid leukemia
por: Lin, Guoqiang, et al.
Publicado: (2021)

Crystal structure of idelalisib tert-butanol monosolvate dihydrate
por: Nerdinger, Sven, et al.
Publicado: (2019)

First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era
por: Urso, Antonio, et al.
Publicado: (2023)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hh7qdbiqp2r388eg84h5qt2st9